ARTICLE SUMMARY:
A $2 billion market growing by double digits has attracted new competitors into ambulatory cardiac monitoring, some of them large strategics. How can a small company differentiate itself in a crowded device-plus-service market where on the surface, it seems that every competitor claims the same advantages? InfoBionic does so with a technology-enabled business model that allows cardiology practices to 100% control the testing process and collect 100% of the reimbursement.
Even before the pandemic, the market for remote or ambulatory cardiac monitoring (ACM) was booming. In the US it’s currently worth $2 billion and it’s growing by double digits. Ambulatory monitoring was developed to aid in the diagnosis of atrial fibrillation (AF) and other transient, difficult-to-detect arrhythmias by providing a view of ECG data over time, and the sheer burden of such arrhythmias, which affect 11 million people in the US, is the principal driver of that rapid growth.
